New perspectives of infections in cardiovascular disease

Current Cardiology Reviews

Volumn 5, Issue 2, 2009, Pages 87-104

  Fong, Ignatius W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BENZNIDAZOLE; BETA LACTAM ANTIBIOTIC; CARVEDILOL; CEFAZOLIN; CEFTRIAXONE; CLOXACILLIN; GENTAMICIN; METICILLIN; NAFCILLIN; NIFURTIMOX; PENICILLIN G; PLECONARIL; PYCNOGENOL; RIFAMPICIN; SPIRONOLACTONE; STREPTOMYCIN; TEICOPLANIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BIOFILM; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHAGAS DISEASE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B3; DEFIBRILLATOR; DEVICE INFECTION; DISORIENTATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART PROTECTION; HEART SURGERY; HUMAN; INFECTION; INSOMNIA; IRRITABILITY; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MENINGITIS; MONOTHERAPY; MYOCARDITIS; NEPHROTOXICITY; NEURITIS; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PERIMYOCARDITIS; PERIODONTAL DISEASE; PERIPHERAL NEUROPATHY; PHOTOSENSITIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; SKIN INJURY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREMOR; TRYPANOSOMA CRUZI; VESTIBULAR DISORDER; VIRUS MYOCARDITIS;

EID: 68549088946     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788166679     Document Type: Review

References (158)

1. Feldman AM, McNamara D. Myocarditis [Review Article]. N Engl J Med 2000; 343: 1388-98.
2. Aretz HT, Billingham ME, Edwards Wd, et al. Myocarditis: a histopathalogical definition and classification. Am J Cardiovasc Pathol 1987; 1: 3-14.
3. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18: 1617-26.
4. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 308: 12-8.
5. Savoia MC, Oxman MN. Myocarditis and pericarditis; In: Mandell GL, Bennett JG, Dolin R (eds), Principles and practice of Infectious Diseases, 6th ed; Philadelphia, Elsevier, Churchill Livingstone, 2005; 1052-70.
6. Cassimatis DC, Atwood JE, Engler RM, et al. Smallbox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004; 43: 1503-10.
7. Fairley CK, Ryan M, Wall PG, Weinberg J. The organisms reported to cause infective myocarditis and pericarditis in England and Wales. J Infect 1996; 32: 223-5.
8. Martino T, Lin P, Sole MJ. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies; In: Robart H. (ed), Human enteroviral infections. Washington, DC, ASM, 1995: 291-351.
9. Kim KS, Hufnagel G, Chapamn NM, Tryacy S. The group B coxsackieviruses and myocarditis. Rev Med Virol 2001; 11: 355-68.
10. Fujioka S, Kitoura Y, Ukimua A, et al. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000; 36: 1920-6.
11. Martin AB, Webber S, Fricker J, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90: 330-9.
12. Bowles NE, Ni J, Kearncy DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42: 466-72.
13. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenovirus 2 and 5. Science 1997: 275: 1320-3.
14. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111: 887-93.
15. Kytö V, Vuorinen T, Saukko P, et al. Cytomegatovirus infection of the heart is common in patients with fatal myocarditis. Clin Infect Dis 2005; 40: 683-8.
16. Hufnagel G, Pankuweit S, Richter A, Schönian U, Maisch B. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz 2000; 25: 279-85.
17. Modlin JF. Coxsackieviruses, Echoviruses and new enterovirus. In: Mandell Gl, Bennett JG, Dolin R (eds); Principles and Practice of Infectious Diseases, 6th Edition, Philadelphia, Elsevier, Churchill Livingston, 2005: 2148-61.
18. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol Mech Dis 2008; 3: 127-55.
19. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman Kl. Clinicopathological description of myocarditis. J Am Coll Cardiol 1991; 18: 1617-26.
20. Olsen EG. Morphological recognition of viral heart disease. Scand J Infect Dis 1993; 88 (suppl): 45-7.
21. Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008; 94: 498-501.
22. Kwai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99: 1091-100.
23. McManus BM, Chow LH, Wilson JE, et al. Direct myocardial injury by enterovirus; a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993; 68: 159-69.
24. Knowlton KU. CVB infection and mechanism of viral cardiomyopathy. Curr Top Microbiol Immunol 2008; 323: 315-35.
25. Kyu B, Matsumori A, Sato Y, Okada I, Chapman NM, Tracy S. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation 1992; 86: 522-30.
26. Li Y, Bourlet T, Andreoletti L. Enteroviral capsid protein VPI is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation 2000; 101: 231-34.
27. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 1992; 89: 314-18.
28. Gluck B, Schmidrke M, Merkle I, Stelzner A, Gemsa D. Persistent expression of cytokines in the chronic stage of CVB 3-induced myocarditis in NMRI mice. J Mol Cell Cardiol 2001; 33: 1615-26.
29. Bauer S, Gottesman G, Sirota L, Litmanovitz I, Ashkenagi S, Levi I. Severe coxsackie virus B infection in preterm newborns treated with plecornaril. Eur J Pediatr 2002; 161: 491-93.
30. Fohlman J, Pauksen K, Hyypia T, et al. Antiviral treatment with WIN 54954 reduces mortality in murine coxsackievirus B3 myocarditis. Circulation 1996; 94: 2254-59.
31. Yue-Chun L, Li-Sha G, Jiang-Hua R, et al. Protective effects of carvedilol in murine model with the coxsackie-virus B3-induced myocarditis. J Cardiovasc Pharmacol 2008; 51: 92-8.
32. Matsumori A, Higuchi H, Shimada M. French maritime pine bark extract inhibits viral replication and prevents development of viral myocarditis. J Card Fail 2007; 13: 785-91.
33. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systemic review. JAMA 2007; 298: 2171-81.
34. Kirchhoff LV. Changing epidemiology and approaches to therapy for Chagas disease. Curr Infect Dis Rep 2003; 5: 59-65.
35. Lelby DA, Herron RM, Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevelance and implications for transfusion transmission. Transfusion 2002; 42: 549-55.
36. Benchimol Barbosa PR. The oral transmission of Chagas disease: an acute form of infection responsible for regional outbreaks. Int J Cardiol 2006; 112: 132-3.
37. Herwaldt BL, Grijalva MJ, Newsome AL, et al. Use of polymerase chain reaction to diagnose the fifth reported US case of autochthonous transmission of Trypanosoma cruzi, in Tennessee, 1998. J Infect Dis 2000; 181: 395-9.
38. Dorn PL, Perniciaro L, Yabsley MJ, et al. Autochthonous transmission of Trypanosoma cruzi, Luisiana. Emerg Infect Dis 2007; 13: 605-7.
39. Bradley KK, Bergman DK, Woods JP, Crutcher JM, Kirchhoff LV. Prevalance of American trypanosomiasis (Chagas disease) among dogs in Oklahoma. J Am Vet Med Assoc 2000; 217: 1853-7.
40. Pung OJ, Banks CW, Jones DN, Krissenger MW. Trypanosoma cruzi in wild raccoons, opossums, and triatomine bugs in southeast Georgia, USA. J Parasitol 1995; 81: 324-6.
41. Centers for Disease Control and Prevention. Blood donor screening for Chagas disease - United States, 2006 - 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 141-3.
42. Girones N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas disease. Curr Top Microbiol Immunol 2005; 296: 89-123.
43. Fonseca SG, Reis MM, Coelho V, et al. Locally produced survival cytokines 1L-15 and 1L-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol 2007; 66: 362-71.
44. Marinho CR, Nunez-Apaza LN, Martins-Santos R, et al. IFN-gamma, but not nitric acid or specific IgG, is essential for the invivo control of low- virulence Sylvio x1014 Trypanosoma cruzi parasites. Scand J Immunol 2007; 66: 297-308.
45. Hyland, KV, Leon, JS, Daniels, MD, et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 2007; 75: 3641-50.
46. Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterim-Borda L, Teixeira MM. Levels of anti-M2 and anti-beta 1 auto-antibodies do not correlate with the degree of heart dysfunction in Chagas' heart diseae. Microbes Infect 2006; 8: 2459-64.
47. Martinelli PM, Camargos ER, Azvedo AA, Chiari E, Morel G, Machado CR. Cardiac NGF and GDNF expression during Trypanosoma cruzi infection in rats. Auton Neurosci Basic 2006; 130: 32-40.
48. Rocha NN, Garcia S, Gimenez LED, et al. Characterization of cardiopulmonary function and cardiac muscarinic and adrenergic receptor density adaptation in C57BL/6 mice with chronic Trypanosoma cruzi infection. Parasitology 2006; 133: 729-37.
49. Ramasawmy R, Cunha-Neto E, Fae KL, et al. The monocyte chemoattractant protein - 1 gene polymorphism is associated with cardiomyopathy in human Chagas disease. Clin Infect Dis 2006; 43: 305-11.
50. Garcia Borras S, Diez C, Cotorruelo C, et al. HLA class II DRB1 polymorphism in Argentinians undergoing chronic Trypanosoma cruzi infection. Ann Clin Biochem 2006; 43: 214-6.
51. Ramasawmy R, Cunha-Neto E, Fae KL, et al. BAT1, a putative anti-inflammatory gene is associated with chronic Chagas cardiomyopathy. J Infect Dis 2006; 193: 1394-9.
52. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348: 1407-13.
53. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy in the indetermine stage of Chagas disease. Am J Trop Med Hyg 1998; 59: 526-9.
54. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 2006; 144: 724-34.
55. The Benefit trial: evaluation of the use of an antiparasitic drug (benznidazole) in the treatment of chronic Chagas disease. http://clinicaltrials.gov.show/NCT100 123916. Accessibility verified October 11, 2007.
56. Vasavada BC. Clinical aspects of the Chagas' heart disease. Int J Cardiol 2007; 115: 279-83.
57. Rassi A, Jr, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006; 355: 799-808.
58. Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrythmias. Pacing Clin Electrophysiol 2006; 29: 467-70.
59. Ramines FJ, Salemi VM, Ianno BM, et al. Aldosterone antagonism in an inflammatory state: evidence of myocardial protection. J Rennin Angioten Aldoster Syst 2006; 7: 162-7.
60. Prendergast BD. The changing face of infective endocarditis. Heart 2006; 92: 879-85.
61. Hoen B, Alla F, Beguinot L, et al. Changing profile of infective endocarditis. Results of a 1-year survey in France. JAMA 2002; 288: 75-81.
62. Tornos P, Lung B, Permanyer-Miralda G, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart 2005; 91: 571-5.
63. Miró JM, del Rio A, Mestres CA. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am 2002; 16: 273-95.
64. Morellion P, Que V-A. Infective endocarditis. Lancet 2004; 363: 139-49.
65. Bourza E, Menasalvas A, Munoz P, et al. Infective endocarditis: a prospective study at the end of the twentieth century - new predisposing conditions, new etiologic agents, and still a high mortality. Medicine (Baltimore) 2001; 80: 298-307.
66. Braun S, Casabe J, Morris A, Corey GR, Cabell CH, International Collaboration Endocarditis-Prospective Cohort Study Investigators. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297: 1354-61.
67. Piroth L, Que YA, Widmer E, et al. The fibrinogen-and fibronectim-binding domains of Staphylococcus aureus fibronectinbinding protein A promote synergistically endothelial invasion and experimental endocarditis. Infect Immun 2008; 76: 3824-31.
68. Darouiche RO, Landon GC, Patti JM, et al. Role of Staphylococcus aureus surface adhesions in orthopedic device infection. J Med Microbiol 1997; 46: 75-9.
69. Green C, Mc Devitt D, Francois P, Vaudaux PE, Lew DP, Foster TJ. Adhesion properties of mutants of Staphylococcus aureus defective in the fibronectin-binding proteins on the expression of Fnb genes. Mol Microbial 1995; 17: 1143-5.
70. Rupp ME, Ulphani JS, Fey PD, Bartsch K, Mak D. Characterization of the importance of polysaccharide intercellular, hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Infect Immun 1999; 67: 2627-32.
71. Darouiche RO. Device-associated infections: a macro-problem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-72.
72. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
73. Kaplan SS, Basfort RE, Kormos RL. Biomaterial-associated impairment of local neutrophils function. Am Soc Artif Internal Organ Transplant J 1990; 36: M172-5.
74. Gray ED, Verstegen M, Peters G, Regelman WE. Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular response. Lancet 1984; 1: 365-7.
75. Ceri H, Olson ME, Strenich C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
76. Nichols WW, Dorrington SM, Slack MPE, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob Agents Chemother 1988; 32: 518-23.
77. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 1994; 91: 200-09.
78. Li JS, Sexton DJ, Mick N, et al. Proposal modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633-38.
79. Miigge A, Daniel WG, Frank G, et al. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation sizes determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989; 14: 631-8.
80. Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic value of echocardiography in patients with infective endocarditis by transesophageal approach: a prospective study. Eur Heart J 1988; 9: 43-53.
81. Reynolds HR, Jagen MA, Tunick PA, Kronzon I. Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era. J Am Soc Echocardiogr 2003; 16: 67-70.
82. Chirillo F, Pedrocco A, DeLeo A, et al. Impact of harmonic imaging on transthoracic echocardiographic identification of infective endocarditis and its complications. Heart 2005; 91: 329-33
83. Jassal DS, Aminbakhsh A, Fang T, et al. Diagnostic value in endocarditis of harmonic transthoracic echocardiography in native-valve endocarditis: comparison with transesophageal echocardiography. Cardiovasc Ultrasound 2007; 5: 20.
84. Zamorano J, de Isla LP, Moura L, et al. Impact of echocardiography in the short and long-term prognosis of patients with infective endocarditis and negative blood cultures. J Heart Valve Dis 2004; 13: 997-04.
85. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Council on Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-e434.
86. Knoll B, Tleyjeh IM, Steckeberg JM, Wilson WR, Baddour CM. Infective endocarditis due to penicillin - resistant viridans group streptococci. Clin Infect Dis 2007; 44: 1585-92.
87. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two week combination therapy. Ann Intern Med 1988; 109: 619-24.
88. Ribera E, Gómez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. Ann Intern Med 1996; 125: 969-74.
89. Fontún J, Navas E, Martinez-Beltran J, et al. Short-term therapy for right-sided endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-5.
90. Lodise TP, Mckinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3731-33.
91. Korzeniowski O, Sande MA, National Collaborative Endocarditis Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parental drugs and in non-addicts. Ann Intern Med 1982; 97: 496-03.
92. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycoside in combination with a β-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-47.
93. Oliason L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycoside be used? Clin Infect Dis 2002; 34: 159-66.
94. Wilson WR, Wilkowske CJ, Wright AI, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100: 816-23.
95. Gavaldá J, Onrubia PL, Gómez M, et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52: 514-7.
96. Gavaldá J, Len O, Miró. JM, et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146: 574-9.
97. Wang A, Athan E, Fowler, VG, Jr, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297: 1354-61.
98. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98: 447-55.
99. Karchmer AW, Archer GL, National Collaborative Endocarditis Study group. Methicillin-resistant Staphylococcus epidermidis prosthetic valve endocarditis: a therapeutic trial. Program and abstracts of 24th Intersci Conf. Antimicrob Agents Chemother, ASM, 1984, Abst #476.
100. Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 (suppl.3): s533-7.
101. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections. A systematic review of the literature. Arch Intern Med 2008; 168: 805-19.
102. Riedel DJ, Weeks E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2008; 52: 2463-7.
103. Sohail MR, Martin KR, Wilson WR, Baddour LM, Harmsen MS, Steckelberg JM. Medical versus surgical management of Staphylococcus aureus prosthetic valve endocarditis. Am J Med 2006; 119: 147-54.
104. Chirouze C, Cabell CH, Fowler VG, Jr, et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration endocarditis merged database. Clin Infect Dis 2004; 38: 1323-7.
105. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, leftsided native valve endocarditis. JAMA 2003; 290: 3207-14.
106. Wang A, Pappas A, Anstrom KJ, et al. The use and effect of surgical therapy for prosthetic valve endocarditis: a prospensity analysis of a multicenter, international cohort. Am Heart J 2005; 150: 1086-91.
107. Akowuak EF, Davies W, Oliver S, et al. Prosthetic valve endocarditis: early and late outcome following medical or surgical treatment. Heart 2003; 89: 269-72.
108. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among medicare beneficiaries: 1990-1999. Am Heart J 2004; 147: 582-6.
109. Eggiman P, Waldovogel FA. Pacemaker and defibrillator infections. In: Waldvogel FA, Bisno AL, eds. Infections associated with indwelling medical devices. Washington DC, American Society for Microbiology Press, 2000; 247.
110. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007; 43: 166-73.
111. Uslan DZ, Sohail MR, St. Sauver JL, et al. Permanent pacemaker and implantable cardioverter defibrillator infection. A population-based study. Arch Intern Med 2007; 167: 669-75.
112. del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction and outcome. Chest 2003; 124: 1451-9.
113. Uslan DZ, Baddour LM. Cardiac device infection: getting to the heart of the matter. Curr Opin Infect Dis 2006; 19: 345-8.
114. Da Costa A, Lelievre H, Kirkorian, G, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998; 1791-5.
115. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104: 1029-33.
116. Klug D, Wallet F, Kacet S, Couracol RJ. Detailed bacteriologic tests to identify the origin of transvenous pacing system infections indicate a high prevalence of multiple organisms. Am Heart J 2005; 149: 322-8.
117. Jassal DS, Weyman, AE. Infective endocarditis in the era of intracardiac devices: an echocardiographic perspective. Rev Cardiovasc Med 2006; 7: 119-29.
118. Chau JD, Wilkoff BL, Lee, I, Juratli N, Longworth PL, Gordon SM. Diagnosis and management of infections involving implantable electrodephysiologic cardiac devices. Ann Intern Med 2000; 133: 604-8.
119. del Rio A, Anguiera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003; 1451-9.
120. Cacoub P, Leprince P, Nataf P, et al. Pacemaker infective endocarditis. Am J Cardiol 1998; 82: 480-4.
121. Bracke FA, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart 2001; 85: 254-9.
122. Baddour LM, Bettman MA, Bolger AF, et al. Non-valvular cardiovascular device-related infections. Circulation 2003; 108: 2015-31.
123. Da Costa A, Kirkorian G, Cucherat M, et al. Antibiotic prophylaxis for permanent pacemaker implantation. A meta-analysis. Circulation 1998; 97: 1796-01.
124. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
125. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
126. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
127. Jespersen CM, Als-Nielson, B, Damgaard M, et al. Randomized placebo controlled multicenter trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. Br Med J 2006; 332: 22-7.
128. Singh, IM, Shishehbor MH, Ansell, BJ. High-density lipoprotein as a therapeutic target: A systematic review. JAMA 2007; 298: 786-98.
129. Tardif JC, Grégorire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis. JAMA 2007; 297: 1675-82.
130. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. Can Med J Assoc 2000; 163: 49-56.
131. Fong IW (ed). Chlamydia pneumoniae and the cardiovascular system. In: Infections and the Cardiovascular System: new perspectives. Kluwer Academic/Plenum Publishers, New York, 2003; 121-77.
132. Fong IW (ed). Periodontal disease and the cardiovascular system. In: Infections and the cardiovascular system: new perspectives. Kluwer academic/Plenum Publishers, New York, 2003; 179-200.
133. Fong IW, Chiu B, Viira E, Tucker W, Wood H, Peeling RW. Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques. J Infect Dis 2002; 186: 1469-73.
134. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999; 7: 6048-55.
135. Li, L, Messas E, Batista EL Jr, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolysoprotein E deficient murine model. Circulation 2002; 105: 861-7.
136. Vehmaan Keula, P, Puolakkaunen M, Sarvas M, Welgus HG, Kovanen PT. Chlamydia pneumoniae proteins induces the 92-KDa gelatinase by human monocyte derived macrophages. Arterioscler Thromb Vasc Biol 2001; 21: E1-8.
137. Schmidt R, Redecke, V, Breitfeld Y, et al. EMMPRIN(CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb Haemostasis 2006; 95: 151-8.
138. Dechend R, Maas M, Greffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscles and endothelial cells activates NF_Kappa B and induces tissue factor and PAI-I expression: a potential link to accelerated atherosclerosis. Circulation 1999; 100: 1369-73.
139. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates development of atherosclerosis and treatment with azithromycin prevent it in a rabbit model. Circulation 1998: 633-6.
140. Fong IW, Chiu B, Viira E, et al. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae - induced atherosclerosis in a rabbit model? Clin Diag Lab Immun 1999; 6: 891-4.
141. Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 1999; 43: 2268-72.
142. Wolf K, Malinverni R, Effect of azithromycin plus rifampin versus that of azithromycin alone on eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. Antimicrob Agents Chemother 1999; 43: 1491-3.
143. Gieffers J, Fullgraf H, Jaln J, Klinger M, Dalhoff K, Katus HA. Chlamydia pneumoniae in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103:351-6.
144. Dechend R, Gieffers J, Dietz R, et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003; 108: 261-5.
145. Schmeck B, Beermann W, N'Guessan, PD, et al. Simvastatin reduces Chlamydophila pneumoniae-mediated histone modification and gene expression in cultured human endothelial cells. Circ Res 2008; 102: 888-95.
146. Liuba P, Pesonen E, Paakkari I, et al. Protective effects of simvastatin on coronary artery function in swine with acute infection. Atherosclerosis 2006; 186: 331-6.
147. Tiirola T, Sinisalo J, Nieminen MS, et al. Chlamydial lipopolysaccharide is present in serum during acute coronary syndrome and correlated with CRP levels. Atherosclerosis 2006; 194: 403-7.
148. Mahdi OS, Horne BD, Mullen K, Muhlestein JB, Byrne GI. Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease. Circulation 2002; 106: 1659-63.
149. Hogan RJ, Mathews SA, Mukhopadhyay, S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004; 72: 1843-55.
150. Borel N, Summersgill JT, Mukhopadhyay S, Miller RD, Ramirez JA, Pospischil A. Evidence for persistent Chlamydia pneumoniae infection of human atheromas. Atherosclerosis 2008; 199: 154-61.
151. Bunk S, Susnea I, Rupp J, et al. Immunoproteomic identification and serological response to novel Chlamydia pneumoniae antigens that are associated with persistent C.pneumoniae infections. J Immun 2008; 180: 5490-8.
152. Arno G, Kaski JC, Smith DA, Akiyu JP, Hughes SE, Baboonian C. Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart 2005; 91: 521-5.
153. Clarke MCH, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12: 1075-80.
154. Schoier J, Hogdahl M, Soderlund G, Kihlstrom E. Chlamydia (Chlamydophila) pnemoniae-induced cell death in human coronary endothelial cells is caspase-independent and accompanied by subcellular translocations of Bax and apoptosis-inducing factor. FEMS Immun Med Microbiol 2006; 47: 207-16.
155. Desvarieux M, Demmer RT, Rundek T, et al. Periodontal micrbiota and carotid intima-meida thickness. The Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111: 576-82.
156. Lu B, Parker D, Eaton CB. Relationship of periodontal attachment loss to peripheral vascular disease: an analysis of NHANES 1999-2002 data. Atherosclerosis 2008; 200: 119-05.
157. Coughlin SR. Protease-activated receptors in hemostatis, thrombosis and vascular biology. J Thromb Haemostasis 2005; 3: 1800-14.
158. Holzhausen M, Spolidario LC, Ellen RP, et al. Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol 2006; 168: 1189-99.